Skip to main content Accessibility help
×
Home

Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

  • Hiroyuki Umegaki (a1), Akio Itoh (a2), Yusuke Suzuki (a1) and Toshitaka Nabeshima (a3)

Abstract

Background: Maintaining continuous pharmacological treatment of patients with dementia is often difficult. In the current study we surveyed the discontinuation of donepezil, a cholinesterase inhibitor, for the treatment of Alzheimer's disease in a Japanese geriatric outpatient clinic in a university hospital.

Methods: Using a retrospective chart review from 1 July 2003 to 30 June 2005, prescriptions of donepezil and the reasons for discontinuing the prescription in a university hospital were determined. The severity of dementia was evaluated by the clinical dementia rating (CDR).

Results: Out of 264 patients, 140 (53.1%) discontinued taking donepezil during the two-year observation period. The mean age of the continued group and the discontinued group did not differ significantly (79.5 ± 6.7, 79.8 ± 6.4, respectively). Kaplan-Meier analysis showed that the patients with more severe cognitive impairment (CDR score = 3) discontinued donepezil earlier and more frequently. The reasons for discontinuation were a change in the doctors treating the patients (n = 71), ineffectiveness (n = 16), gastrointestinal side-effects (n = 11), and others (n = 41). In patients with CDR = 1 or 2, changes of doctors were the most frequent reason for discontinuation. However, in patients with CDR = 3, ineffectiveness of the medication was the major reason for discontinuation.

Conclusion: Donepezil was frequently discontinued, and the rate of discontinuation was higher in patients with advanced dementia.

Copyright

Corresponding author

Correspondence should be addressed to: Hiroyuki Umegaki, Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. Phone: +81 52 744 2365; Fax: +81 52 744 2371. Email: umegaki@med.nagoya-u.ac.jp.

References

Hide All
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Systematic Review, 25, CD005593.
Blennow, K., de Leon, M. J. and Zetterberg, H. (2006). Alzheimer's disease. Lancet, 368, 387–340.
Evans, M., Ellis, A., Watson, D. and Chowdhury, T. (2000). Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. International Journal of Geriatric Psychiatry, 15, 5053.
Frankfort, S. V. et al. (2005). Discontinuation of rivastigmine in routine clinical practice. International Journal of Geriatric Psychiatry, 20, 11671171.
Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. and Martin, R. L. (1982). A new clinical scale for the staging of dementia. British Journal of Psychiatry, 140, 566567.
Mauskopf, J. A., Paramore, C., Lee, W. C. and Snyder, E.H. (2005). Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy, 11, 231251.
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412.
Suh, D. C., Thomas, S. K., Valiyeva, E., Arcona, S. and Vo, L. (2005). Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs & Aging, 22, 695–670.
Umegaki, H., Suzuki, Y, Kuzuya, M. and Iguchi, A. (2007). Attitudes of Japanese general practitioners towards referrals of patients with dementia. Nippon Ronen Igakkai Zasshi, 44, 102106.

Keywords

Related content

Powered by UNSILO

Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

  • Hiroyuki Umegaki (a1), Akio Itoh (a2), Yusuke Suzuki (a1) and Toshitaka Nabeshima (a3)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.